Quantitative PCR Analysis for Bcl-2/IgH in a Phase III Study of Yttrium-90 Ibritumomab Tiuxetan As Consolidation of First Remission in Patients With Follicular Lymphoma
| Autor: | Sameena Iqbal, Franck Morschhauser, Anton Hagenbeek, Karin E. Summers, Andrew Lister, Ama Z. S. Rohatiner, Barbara Putz, Jens Kuhlmann, Lindsey K. Goff, Tom Louton, Michael Kunz |
|---|---|
| Přispěvatelé: | Cancer Center Amsterdam, Clinical Haematology |
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Ibritumomab tiuxetan Follicular lymphoma Polymerase Chain Reaction Gastroenterology Disease-Free Survival law.invention Randomized controlled trial law Internal medicine Antineoplastic Combined Chemotherapy Protocols Gene Order medicine Humans Yttrium Radioisotopes Lymphoma Follicular Aged business.industry Remission Induction Hazard ratio Antibodies Monoclonal Middle Aged medicine.disease Minimal residual disease Genes bcl-2 Lymphoma Radiation therapy Treatment Outcome Real-time polymerase chain reaction Oncology Female Radiotherapy Adjuvant Immunoglobulin Heavy Chains Nuclear medicine business medicine.drug |
| Zdroj: | Journal of clinical oncology, 27(36), 6094-6100. American Society of Clinical Oncology |
| ISSN: | 1527-7755 0732-183X |
| Popis: | Purpose The randomized First-Line Indolent Trial (FIT) was conducted in patients with advanced follicular lymphoma (FL), to evaluate the safety and efficacy of yttrium-90 (90Y) ibritumomab tiuxetan given as consolidation of complete or partial remission. This study of minimal residual disease was undertaken in parallel, to determine the rate of conversion from bcl-2 polymerase chain reaction (PCR) –detectable to –undetectable status and the corresponding effect on progression-free survival (PFS). Patients and Methods Blood samples from 414 patients (90Y-ibritumomab, n = 208; control, n = 206) were evaluated using real-time quantitative polymerase chain reaction (RQ-PCR); 186 were found to have the bcl-2 rearrangement and were thus eligible for inclusion in the RQ-PCR analysis. Results Overall, 90% of treated patients converted from bcl-2 PCR–detectable to –undetectable disease status, compared with 36% in the control group. Treatment significantly prolonged median PFS in patients converting to bcl-2 PCR-undetectable status (40.8 v 24.0 months in the control group; P < .01, hazard ratio [HR], 0.399). In patients who had bcl-2 PCR-detectable disease at random assignment, treatment significantly prolonged median PFS (38.4 v 8.2 months in the control group; P < .01, HR, 0.293). Conclusion Eradication of PCR-detectable disease occurred more frequently after treatment with 90Y-ibritumomab tiuxetan and was associated with prolongation of PFS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|